Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Medicus Pharma Ltd. (NASDAQ:MDCX) is a clinical-stage biotechnology company that went public in November 2024. Founded as a biotech venture focused on developing innovative cancer treatments, the company specializes in advancing non-invasive therapeutic solutions for skin cancer. As a recently public entity, Medicus represents an early-stage biotech firm transitioning from private development to public markets while pursuing clinical trials for its novel therapeutic candidates.
Latest newsMore news →
Medicus Pharma Ltd. issued 8,529,412 restricted common shares to certain officers and employees at $0.1705 per share, worth about $1.45 million, in lieu of cash bonuses under a private placement exempt from registration.9d agoMedicus Pharma published abridged final Phase 2 clinical study report results for its SkinJect D-MNA patch, identifying the 200 µg dose as the lead development dose.10d agoMedicus Pharma raised about $40 million through equity and debt financing during the first half of 2026.38d ago